Tandem Diabetes price target lowered to $52 from $61 at Cowen

Cowen analyst Joshua Jennings lowered the firm’s price target on Tandem Diabetes to $52 from $61 and keeps an Outperform rating on the shares. The analyst said the margin guidance is flat and slightly down year-over-year respectively which may pressure the stock near term but we still we see long-term value in the shares.